Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT): 13 pipeline candidates · 9 upcoming catalysts · ~14 mo cash runway · 19 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.2 months
D/E 0.19 · 0% dilution
Lead: Phase 3
13 candidates
9 upcoming, next in ~149d
4 buys · 0 sells (180d)
A transparent, data-derived signal for Summit Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.9B
Cash
$106.8M
Quarterly Burn
$122.3M
Runway
14.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (13 candidates)
| Drug | Phase |
|---|---|
| ak112 | Phase 3 |
| AK112 Injection | Phase 3 |
| Drug | Phase 3 |
| Ezutromid | Phase 2 |
| Fidaxomicin | Phase 2 |
| ivonescimab | Phase 3 |
| ivonescimab | Phase 3 |
| ivonescimab + ligufalimab | Phase 3 |
| Ivonescimab Injection | Phase 3 |
| Ridinilazole | Phase 2 |
Showing 10 of 13 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Binary FDA approval decision — outcome can sharply revalue the stock.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
226
Total value held
$2.21B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 36,391,063 | $690.0M |
| vanguard capital management llc | 11,423,604 | $216.6M |
| fmr llc | 10,853,199 | $205.8M |
| blackrock, inc. | 9,653,758 | $183.0M |
| state street corp | 7,028,160 | $133.3M |
| vanguard portfolio management llc | 5,233,252 | $99.2M |
| geode capital management, llc | 3,315,854 | $62.9M |
| susquehanna international group, llp | 2,410,733 | $45.7M |
| d. e. shaw & co., inc. | 2,242,229 | $42.5M |
| morgan stanley | 1,650,591 | $31.3M |
Showing top 10 of 226 institutional holders of Summit Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Summit Therapeutics Inc.'s pipeline?
Summit Therapeutics Inc. (SMMT) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Summit Therapeutics Inc.'s lead drug candidate?
Summit Therapeutics Inc.'s most advanced tracked candidate is ak112 (Phase 3) for Non-Squamous Non-small Cell Lung Cancer.
What is Summit Therapeutics Inc.'s next catalyst?
Summit Therapeutics Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: ivonescimab" — expected November 14, 2026.
What is Summit Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Summit Therapeutics Inc. has approximately 14.2 months of cash runway.
What is Summit Therapeutics Inc.'s market capitalization?
Summit Therapeutics Inc.'s market capitalization is approximately $10.9B.
Get the full picture on Summit Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.